The prevalence of aminoglycoside-modifying enzyme genes (aac (6′)-I, aac (6′)-II, ant (2″)-I, aph (3′)-VI) in Pseudomonas aeruginosa

Clinics

Volumn 66, Issue 9, 2011, Pages 1519-1522

  Vaziri, Farzam ^a   Peerayeh, Shahin Najar ^a   Nejad, Qorban Behzadian ^a   Farhadian, Abbas ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Aac (6 ) ii; Ant (2 ) i; Antibiotic; Pseudomonas aeruginosa; Resistance

Indexed keywords

ACYLTRANSFERASE; AMINOGLYCOSIDE; AMINOGLYCOSIDE ACETYLTRANSFERASE; ANTIINFECTIVE AGENT; BACTERIAL DNA; GENTAMICIN 2'' NUCLEOTIDYLTRANSFERASE; GENTAMICIN 2''-NUCLEOTIDYLTRANSFERASE; KANAMYCIN KINASE; NUCLEOTIDYLTRANSFERASE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; FEMALE; GENETICS; HUMAN; IRAN; MALE; METABOLISM; PSEUDOMONAS AERUGINOSA;

ACETYLTRANSFERASES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; IRAN; KANAMYCIN KINASE; MALE; NUCLEOTIDYLTRANSFERASES; PSEUDOMONAS AERUGINOSA;

EID: 80053524592     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000900002     Document Type: Article

References (27)

1. Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med. 2002;95(suppl 41):22-6.
2. Park YJ. Prevalence of Ambler class A and D b-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother. 2005;56:122-7. doi: 10.1093/jac/dki160.
3. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2000;44:710-2.
4. Giamarellou H. Therapeutic guidelines for Pseudomonas aeruginosa infections. Int J antimicrob Agen. 2000;16:103-6. doi: 10.1016/S0924-8579(00)00212-0.
5. Dubois V, Arpin C, Dupart V, Scavelli A, Coulange L, Andre C, et al. blactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). J Antimicrob Chemother. 2008;62:316-23. doi: 10.1093/jac/dkn174.
6. Islam S, Oh H, Jalal S, Karpati F, Ciofu O, Høiby N, et al. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect. 2009;15:60-6. doi: 10.1111/j.1469-0691.2008.02097.x.
7. Macfarlane E, Kwasnicka A, Hancock R. Role of Pseudomonas aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiol. 2000;146:2543-54.
8. Sadovskaya I, Vinogradov E, Li J, Hachani A, Kowalska K, Filloux A. High-level antibiotic resistance in Pseudomonas aeruginosa biofilm: the ndvB gene is involved in the production of highly glycerol-phosphorylated b-(1R3)-glucans, which bind aminoglycosides. Glycobiol. 2010;20:895-904 doi: 10.1093/glycob/cwq047.
9. Doi Y, Ghilardi AC, Adams J, de Oliveira GD, Paterson DL. High prevalence of metallo- b-lactamase and 16S rRNA methylase coproduction among imipenem- resistant Pseudomonas aeruginosa isolates in Brazil. Antimicrob Agents Chemother. 2007;51:3388-90 doi: 10.1128/AAC.00443-07.
10. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics aminoglycoside resistance genes and familial relationship of the aminoglycoside modifying enzymes. Microbiol Rev. 1993;57:138-63.
11. Smith CA, Baker EN. Aminoglycoside antibiotic resistance by enzymatic deactivation. Curr Drug Targets Infect Disord. 2002;2:143-60 doi: 10.2174/1568005023342533.
12. Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y. Global spread of multiple aminoglycoside resistance genes. Emerg Infect Dis. 2005;11: 951-3.
13. Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ. The most frequently occurring aminoglycoside resistance mechanisms- combined results of surveys in eight regions of the world. J Chemother. 1995;7(Suppl. 2):17-30.
14. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:479-87 doi: 10.1128/AAC.49.2.479-487.2005.
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document M100-S17. CLSI, 2007 Wayne, PA.
16. Kim JY, Park YJ, Kwon HJ, Han K, Kang MW, Woo GJ. Occurrence and mechanisms of amikacin resistance and its association with b-lactamases in Pseudomonas aeruginosa: a Korean nationwide study. J Antimicrob Chemother. 2008;62:479-83 doi: 10.1093/jac/dkn244.
17. Cavallo J, Hocquet D, Plesiat P, Fabre R, Roussel-Delvallez M. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J Antimicrob Chemother. 2007;59: 1021-4 doi: 10.1093/jac/dkm076.
18. Estahbanati H, Kashani P, Ghanaatpisheh F. Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns. 2002;28:340-8 doi: 10.1016/S0305-4179(02)00024-4.
19. Busch-Sorensen C, Sonmezoglu M, Frimodt-Moller N, Hojbjerg T, Miller GH, Espersen F. Aminoglycoside resistance mechanisms in Enterobacteriaceae and Pseudomonas spp. from two Danish hospitals: correlation with type of aminoglycoside used. APMIS. 1996;104:763-8.
20. Over U, Gur D, Unal S, Miller GH. The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey. Clin Microbiol Infect. 2001;7:470-8.
21. Phillips I, King A, Shannon K. Prevalence and mechanisms of aminoglycoside resistance. A ten-year study. Am J Med. 1986;80:48-55.
22. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, et al. The most frequent aminoglycoside resistance mechanisms changes with time and geographic area: a reflection of aminoglycoside usage patterns. Clin Infect Dis. 1997;24:S46-62 doi: 10.1093/clinids/24.Supplement_1.S46.
23. Park YJ. Aminoglycoside Resistance in Gram-negative Bacilli. Korean J Clin Microbiol. 2009;12:57-61.
24. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist. 2010;13:151-71 doi: 10.1016/j.drup.2010.08.003.
25. Strateva T, Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Medic Microbiol. 2009;58:1133-48 doi: 10.1099/jmm.0.009142-0.
26. Haddad J, Kotra LP, Llano-Sotelo B, Kim C, Azucena EF, Liu M, et al. Design of novel antibiotics that bind to the ribosomal acyltransfer site. J Am Chem Soc. 2002;124:3229-37 doi: 10.1021/ja011695m.
27. Page M, Heim J. Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol. 2009;9:558-65 doi: 10.1016/j.coph.2009.08.006.